BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Cidara Therapeutics, Inc. (CDTX) on Monday announced positive results from its mid-stage trial evaluating CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64.

A 41-year-old woman from northwestern Cambodia's Siem Reap province has been confirmed for H5N1 human avian influenza, ...

The latest edition of Poultry World is available online. In this edition we visit a former investment banker who had built a ...

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...

Cidara Therapeutics' shares were set to rally at the opening bell after a trial of the biotechnology company's non-vaccine preventative of seasonal influenza met all key goals. In premarket trading, ...